• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Acute Coronary Syndrome Market Trends

    ID: MRFR/Pharma/4326-HCR
    100 Pages
    Rahul Gotadki
    September 2025

    Acute Coronary Syndrome Market Research Report by Type (Unstable Angina, Nstemi), by Diagnosis (Blood Tests, Imaging, Stress Test), Treatment (Medication, Surgery), End-User (Hospitals & Clinics, Diagnostic Centers) - Forecast Till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Acute Coronary Syndrome Market Research Report - Forecast to 2032 Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Trends

    Key Emerging Trends in the Acute Coronary Syndrome Market

    The market trends in the acute coronary syndrome (ACS) sector reflect a dynamic landscape driven by advances in medical research, diagnostic technologies, and evolving treatment strategies. One interesting fact is that ACS is becoming increasingly common globally due to reasons such as lack of exercise, bad eating habits and an aged society. Increased knowledge coupled with increased efforts towards preventing cardiovascular disease aid in early diagnosis and intervention. It shows that there is urgent need for innovative interventions addressing the increasing burden of all sorts of issues making up ACS like unstable angina pectoris and myocardial infarction. New generation diagnostic tools which are high-sensitive cardiac troponin assays as well as angiography and Computed Tomography Angiography have completely transformed the quick identification of Acute Coronary Syndrome (ACS) at its earliest manifestation. High sensitivity rapid Troponin tests enable health care providers to rapidly evaluate myocardial damage which assists in prompt decision making. This kind of improvement in diagnostics ensures quick identification resulting from early intervention in this condition. The pharmaceutical industry has taken a lead role in regard to cardiovascular safety providing numerous drug options meant for ACS patients. Some common medications prescribed include antiplatelet agents, beta-blockers and statins among others for management of ACS hence reducing risks related to recurrent events. Ongoing studies are also being done on new antithrombotic agents, interventions to modulate inflammation and RNA-based therapies among others. Such a trend demonstrates that treatments continue to be fine-tuned so as to increase patient outcomes while at the same time reducing overall burdensome nature of ACS. Personalized medicine plays an ever-greater part in shaping how ACS markets are run today. Customizing treatment based on specific traits including genetics or presence of other illnesses has become quite standard these days. Precision medicine intends on optimizing therapeutic benefits with minimal adverse effects hence making it more prospective for effective management of ACS. Collaborations between healthcare practitioners, researchers and pharmaceutical industries have an effect on ACS service delivery. The heart teams comprise of cardiologists, interventionalists and other specialists who offer a complete approach to patient care. These partners also contribute to clinical trials and research initiatives aimed at increasing the understanding of ACS pathophysiology and options for treatment. Telemedicine and digital health technologies are becoming integral components of ACS care, particularly in post-event follow-up and preventive care. These technologies facilitate remote consultations, patient monitoring, and the delivery of cardiac rehabilitation programs, enhancing accessibility for individuals recovering from ACS events. This trend aligns with the broader adoption of digital healthcare solutions and offers a convenient and patient-friendly approach to managing cardiovascular health. There is an increased recognition of the role played by lifestyle interventions as well as preventive measures in ACS management. Lifestyle changes such as smoking cessation, healthy eating habits among others are being included in the overall treatment plan for patients with ACS due to its high importance in treating risk factors that are involved in its development like poor dieting, lack of exercise among others. This trend highlights a holistic as well as proactive way towards dealing with cardiovascular issues while avoiding repetitions.

    Market Summary

    The Global Acute Coronary Syndrome Market is projected to experience substantial growth from 8.45 USD Billion in 2024 to 17.7 USD Billion by 2035.

    Key Market Trends & Highlights

    Acute Coronary Syndrome Key Trends and Highlights

    • The market is expected to grow at a compound annual growth rate (CAGR) of 6.97% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 17.7 USD Billion, indicating robust expansion.
    • In 2024, the market is valued at 8.45 USD Billion, reflecting a strong foundation for future growth.
    • Growing adoption of advanced diagnostic technologies due to increasing prevalence of cardiovascular diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 8.45 (USD Billion)
    2035 Market Size 17.7 (USD Billion)
    CAGR (2025-2035) 6.97%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Portola Pharmaceuticals, Inc. (U.S.), AbbVie Inc. (U.S.), AstraZeneca (U.K), Amgen Inc. (U.S.), Bayer AG (Germany), DAIICHI SANKYO COMPANY, LIMITED. (Japan), Eli Lilly and Company (U.S.), GlaxoSmithKline Plc. (U.K), Sanofi (Paris), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.)

    Market Trends

    The increasing prevalence of risk factors such as obesity and diabetes is likely to drive the demand for innovative treatments and preventive measures in the Acute Coronary Syndrome market.

    Centers for Disease Control and Prevention (CDC)

    Acute Coronary Syndrome Market Market Drivers

    Market Trends and Projections

    Growing Awareness and Education

    The rising awareness regarding cardiovascular health and the importance of early detection of acute coronary syndrome is driving the Global Acute Coronary Syndrome Market Industry. Educational campaigns aimed at both healthcare professionals and the general public are increasingly emphasizing the risk factors and symptoms associated with acute coronary syndrome. This heightened awareness is leading to earlier diagnosis and treatment, which is crucial for improving patient outcomes. As more individuals recognize the signs and seek medical attention promptly, the demand for related healthcare services and products is expected to surge, further stimulating market growth.

    Increased Healthcare Expenditure

    Rising healthcare expenditure across various nations is a crucial factor propelling the Global Acute Coronary Syndrome Market Industry. Governments and private sectors are investing more in healthcare infrastructure, leading to enhanced access to diagnostic and therapeutic services for acute coronary syndrome. For example, countries are allocating substantial budgets to cardiovascular health initiatives, which include screening programs and public awareness campaigns. This increased funding is likely to facilitate the adoption of advanced treatment options, thereby contributing to a projected compound annual growth rate of 6.97% from 2025 to 2035, as the market adapts to the growing demand for effective cardiovascular care.

    Regulatory Support and Guidelines

    Supportive regulatory frameworks and clinical guidelines are fostering growth in the Global Acute Coronary Syndrome Market Industry. Regulatory bodies are increasingly endorsing new treatment protocols and technologies that enhance patient care. For instance, updated clinical guidelines from health organizations promote the use of novel therapies and interventions for acute coronary syndrome, ensuring that healthcare providers are equipped with the latest evidence-based practices. This regulatory backing not only boosts confidence among healthcare professionals but also encourages investment in research and development, thereby contributing to the overall expansion of the market.

    Advancements in Medical Technology

    Technological innovations in diagnostics and treatment methodologies are significantly influencing the Global Acute Coronary Syndrome Market Industry. The development of advanced imaging techniques, such as cardiac MRI and CT angiography, enhances the accuracy of diagnosis, allowing for timely interventions. Moreover, the introduction of minimally invasive surgical procedures and novel pharmacological therapies contributes to improved patient outcomes. As these technologies evolve, they are expected to drive market growth, with projections indicating a market value of 17.7 USD Billion by 2035. This trend reflects the industry's commitment to integrating cutting-edge technology in the management of acute coronary syndrome.

    Rising Prevalence of Cardiovascular Diseases

    The increasing incidence of cardiovascular diseases globally is a primary driver for the Global Acute Coronary Syndrome Market Industry. As lifestyle-related factors such as obesity, sedentary behavior, and unhealthy diets become more prevalent, the number of individuals at risk for acute coronary syndrome rises. For instance, data indicates that cardiovascular diseases account for approximately 31% of all global deaths, underscoring the urgent need for effective management and treatment options. This growing health crisis is projected to elevate the market value to 8.45 USD Billion in 2024, highlighting the industry's response to this pressing health challenge.

    Market Segment Insights

    Regional Insights

    Key Companies in the Acute Coronary Syndrome Market market include

    Industry Developments

    BioCardia, Inc. stated in October 2021 that the first patient in their CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for refractory angina has been treated in Acute Coronary Syndrome.

    The Independent Data Monitoring Committee approved XyloCor Therapeutics' Phase 2 trial of XC001 for refractory angina in July 2021. (IDMC). The greatest dose was given to three people with refractory angina in this study.

    Intended Audience

      • Pharmaceutical Companies
      • Biotechnological Institutes
      • Government and Private Laboratories
      • Research and Development (R&D) Companies
      • Medical Research Laboratories
      • Market Research and Consulting Service Providers

    Future Outlook

    Acute Coronary Syndrome Market Future Outlook

    The Global Acute Coronary Syndrome Market is projected to grow at a 6.97% CAGR from 2024 to 2035, driven by advancements in treatment technologies and increasing prevalence of cardiovascular diseases.

    New opportunities lie in:

    • Invest in AI-driven diagnostic tools to enhance early detection of Acute Coronary Syndrome.
    • Develop personalized medicine approaches to improve treatment efficacy and patient outcomes.
    • Expand telemedicine services for remote monitoring and management of cardiovascular patients.

    By 2035, the market is expected to exhibit robust growth, reflecting advancements in care and increasing global demand.

    Market Segmentation

    Intended Audience

    • Market Research and Consulting Service Providers
    • Medical Research Laboratories
    • Research and Development (R&D) Companies
    • Government and Private Laboratories
    • Biotechnological Institutes
    • Pharmaceutical Companies

    Recent Development

    • Market Research and Consulting Service Providers
    • Medical Research Laboratories
    • Research and Development (R&D) Companies
    • Government and Private Laboratories
    • Biotechnological Institutes
    • Pharmaceutical Companies

    Acute Coronary Syndrome Market Key Players

    • Merck & Co., Inc. (U.S.)
    • Novartis AG (Switzerland)
    • Sanofi (Paris)
    • GlaxoSmithKline Plc. (U.K)
    • Eli Lilly and Company (U.S.)
    • DAIICHI SANKYO COMPANY, LIMITED. (Japan)
    • Bayer AG (Germany)
    • Amgen Inc. (U.S.)
    • AstraZeneca (U.K)
    • AbbVie Inc.  (U.S.)
    • Portola Pharmaceuticals, Inc. (U.S.)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • Johnson & Johnson Services, Inc. (U.S.)
    • Boehringer Ingelheim International GmbH (Germany)
    • Market Research and Consulting Service Providers
    • Medical Research Laboratories
    • Research and Development (R&D) Companies
    • Government and Private Laboratories
    • Biotechnological Institutes
    • Pharmaceutical Companies

    Report Scope

    Report Attribute/Metric Details
    Market Size 2022 NA (USD Billion)
    Market Size 2023 NA (USD Billion)
    Market Size 2032 15.2 (USD Billion)
    Compound Annual Growth Rate (CAGR) 5.3 % (2024- 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2022
    Market Forecast Period 2023 - 2032
    Historical Data 2019 - 2022
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Portola Pharmaceuticals, Inc. (U.S.), AbbVie Inc. (U.S.), AstraZeneca (U.K), Amgen Inc. (U.S.), Bayer AG (Germany), DAIICHI SANKYO COMPANY, LIMITED. (Japan), Eli Lilly and Company (U.S.), GlaxoSmithKline Plc. (U.K), Sanofi (Paris), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.)
      Key Market Opportunities Increasing healthcare expenditure increasing availability of funds for research
      Key Market Drivers The increasing prevalence of coronary heart disease Growing geriatric population Growing obese population

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    At what CAGR is the Acute Coronary Syndrome Market predicted to grow during the forecast period?

    Acute Coronary Syndrome Market is projected to grow at a 5.3% CAGR between 2023-2032.

    Which region is expected to lead the Acute Coronary Syndrome Market?

    The Americas is expected to lead the Acute Coronary Syndrome Market.

    What are different end users of Acute Coronary Syndrome Market?

    Different end users of Acute Coronary Syndrome Market include academic institutes, diagnostic centers, hospitals and clinics, and others.

    What are the key factors driving the Acute Coronary Syndrome Market?

    Growing obese population and rising prevalence of diabetes is adding market growth.

    Which factors may limit the Acute Coronary Syndrome Market growth?

    High cost and lack of awareness may limit market growth.

    1. Chapter 1. Report Prologue
    2. Chapter 2. Market Introduction
      1. Definition
      2. Scope of the Study
        1. Research Objective
        2. Assumptions
        3. Limitations Chapter 3. Research Methodology
      3. Introduction
      4. Primary Research
      5. Secondary research
      6. Market Size Estimation
    3. Chapter 4. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
      5. Macroeconomic Indicators
      6. Technology Trends & Assessment Chapter
      7. Porter’s Five Forces Analysis
    4. Bargaining Power of Suppliers
      1. Bargaining Power of Buyers
    5. Threat of New Entrants
      1. Threat of Substitutes
        1. Intensity of Rivalry
      2. Value Chain Analysis
      3. Investment Feasibility Analysis
      4. Pricing Analysis
    6. Chapter 6. Global Acute Coronary Syndrome Market, by Type
      1. Introduction
      2. Unstable angina Market Estimates & Forecast, 2023–2032
      3. ST-Elevation Myocardial Infarction (STEMI)
    7. Market Estimates & Forecast, 2023–2032
      1. Non-ST-Elevation Myocardial Infarction (NSTEMI)
    8. Market Estimates & Forecast, 2023–2032 Chapter
      1. Introduction
      2. Blood Tests
    9. Market Estimates & Forecast, 2023–2032
      1. Imaging
    10. Market Estimates & Forecast, 2023–2032
      1. Myocardial Perfusion Imaging (MPI)
        1. Computerized Tomography (CT) Angiogram
        2. Echocardiogram
        3. Coronary Angiogram
        4. Others
      2. Stress Test
      3. Others
    11. Chapter 8. Global Acute Coronary Syndrome Market, by Treatment
      1. Introduction
      2. Medication
    12. Market Estimates & Forecast, 2023–2032
      1. Thrombolytics
    13. Market Estimates & Forecast, 2023–2032
      1. Nitroglycerin
    14. Market Estimates & Forecast, 2023–2032
      1. Antiplatelet Drugs
    15. Market Estimates & Forecast, 2023–2032
      1. Aspirin
        1. Clopidogrel
        2. Beta Blockers
    16. Market Estimates & Forecast, 2023–2032
      1. Metoprolol
        1. Nadolol
        2. Statins Market
    17. Estimates & Forecast, 2023–2032
      1. Atorvastatin
        1. Simvastatin
        2. Others
      2. Surgery Market Estimates & Forecast, 2023–2032
        1. Angioplasty & Stenting
        2. Coronary Bypass Surgery
        3. Others
    18. Chapter 9. Global Acute Coronary
    19. Syndrome Market, by End-User
      1. Introduction
      2. Hospital & Clinics
    20. Market Estimates & Forecast, 2023–2032
      1. Diagnostic Centers
    21. Market Estimates & Forecast, 2023–2032
      1. Academic Institutes
    22. Market Estimates & Forecast, 2023–2032
      1. Others Chapter
      2. Introduction
      3. America
        1. North America
        2. South America
      4. Europe
        1. Western Europe
        2. Eastern Europe
      5. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia
        5. Republic of Korea
        6. Rest of Asia Pacific
      6. The Middle East & Africa
        1. United Arab Emirates
        2. Saudi Arabia
        3. Oman
        4. Kuwait
        5. Qatar
        6. Rest of the Middle East & Africa
    23. Chapter 11. Company Landscape
      1. Introduction
      2. Market Share Analysis
      3. Key Development & Strategies
        1. Key Developments
    24. Chapter
    25. Company Profiles
      1. Boehringer Ingelheim International GmbH
        1. Company Overview
        2. Type Overview
        3. Financials
        4. Key Developments
        5. SWOT Analysis
      2. Johnson & Johnson Services, Inc.
        1. Company Overview
        2. Type Overview
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
      3. Teva Pharmaceutical Industries Ltd.
        1. Company Overview
        2. Type Overview
        3. Financial Overview
        4. Key Development
        5. SWOT Analysis
      4. Portola Pharmaceuticals, Inc.
        1. Company Overview
        2. Type/Business Segment Overview
        3. Financial Overview
        4. Key Development
        5. SWOT Analysis
      5. AbbVie Inc.
        1. Company Overview
        2. Type Overview
        3. Financial overview
        4. Key Developments
        5. SWOT Analysis
      6. AstraZeneca
        1. Company Overview
        2. Type Overview
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
      7. Amgen Inc.
        1. Overview
        2. Type Overview
        3. Financials
        4. Key Developments
        5. SWOT Analysis
      8. Bayer AG
        1. Overview
        2. Type Overview
        3. Financials
        4. Key Developments
        5. SWOT Analysis
      9. DAIICHI SANKYO COMPANY, LIMITED.
        1. Overview
        2. Type Overview
        3. Financials
        4. Key Developments
        5. SWOT Analysis
      10. Eli Lilly and Company
        1. Overview
        2. Type Overview
        3. Financials
        4. Key Developments
        5. SWOT Analysis
      11. GlaxoSmithKline Plc.
        1. Overview
        2. Type Overview
        3. Financials
        4. Key Developments
        5. SWOT Analysis
      12. Sanofi
        1. Overview
        2. Type Overview
        3. Financials
        4. Key Developments
        5. SWOT Analysis
      13. Novartis AG
        1. Overview
        2. Type Overview
        3. Financials
        4. Key Developments
        5. SWOT Analysis
      14. Merck & Co., Inc.
        1. Overview
        2. Type Overview
        3. Financials
        4. Key Developments
        5. SWOT Analysis
      15. Others
    26. Chapter
    27. MRFR Conclusion
      1. Key Findings
    28. From CEO’s View Point
      1. Unmet Needs of the Market
      2. Key Companies to Watch
      3. Prediction of Acute Coronary Syndrome Market Chapter
    29. & Forecast, 2023–2032, (USD Million)
    30. Syndrome Market, by Region, 2023–2032, (USD Million)
    31. Coronary Syndrome Market, by Type, 2023–2032, (USD Million)
    32. Acute Coronary Syndrome Market, by Diagnosis, 2023–2032, (USD Million) (USD Million) (USD Million 2023–2032, (USD Million)
    33. Market, by Diagnosis, 2023–2032, (USD Million)
    34. Acute Coronary Syndrome Market, by Treatment, 2023–2032, (USD Million) (USD Million) (USD Million) (USD Million) (USD Million) (USD Million) (USD Million) 2023–2032, (USD Million)
    35. by Treatment, 2023–2032, (USD Million)
    36. Syndrome Market, by End-User, 2023–2032, (USD Million)
    37. America Acute Coronary Syndrome Market, by Type, 2023–2032, (USD Million) (USD Million) 2023–2032, (USD Million)
    38. Market, by End-User, 2023–2032, (USD Million)
    39. Syndrome Market, by Type, 2023–2032, (USD Million)
    40. Coronary Syndrome Market, by Diagnosis, 2023–2032, (USD Million)
    41. Market, by Diagnosis, 2023–2032, (USD Million)
    42. Acute Coronary Syndrome Market, by Treatment, 2023–2032, (USD Million) (USD Million) 2023–2032, (USD Million)
    43. Market, by Diagnosis, 2023–2032, (USD Million)
    44. Acute Coronary Syndrome Market, by Treatment, 2023–2032, (USD Million) (USD Million) 2023–2032, (USD Million)
    45. Market, by Diagnosis, 2023–2032, (USD Million)
    46. Acute Coronary Syndrome Market, by Treatment, 2023–2032, (USD Million) (USD Million)
    47. Market, by Type, 2023–2032, (USD Million)
    48. Africa Acute Coronary Syndrome Market, by Diagnosis, 2023–2032, (USD Million) 2023–2032, (USD Million)
    49. Coronary Syndrome Market, by End-User, 2023–2032, (USD Million) LIST OF FIGURES
    50. Acute Coronary Syndrome Market Syndrome Market
    51. Acute Coronary Syndrome Market Share, by Region, 2023
    52. Acute Coronary Syndrome Market Share, by Country, 2023
    53. Coronary Syndrome Market Share, by Country, 2023
    54. Coronary Syndrome Market Share, by Country, 2023
    55. & Africa Acute Coronary Syndrome Market Share, by Country, 2023
    56. Ingelheim International GmbH: Segmental Revenue
    57. International GmbH: Geographical Revenue Inc.: Key Financials Revenue
    58. Pharmaceutical Industries Ltd.: Segmental Revenue
    59. Industries Ltd.: Geographical Revenue Key Financials Inc.: Key Financials
    60. AbbVie Inc.: Geographical Revenue Revenue Revenue Key Financials Geographical Revenue
    61. SANKYO COMPANY, LIMITED.: Geographical Revenue Key Financials
    62. Co., Inc.: Key Financials

    Acute Coronary Syndrome Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study

    Smartphone Motherboard Parts Manufacturing Research